By Puyaan Singh and Christy Santhosh April 30 (Reuters) - Companies developing cannabis-based medicines say U.S. moves to ...

A controversial federal shift is reshaping cannabis taxes, boosting some medical-only operators while complicating life for ...

DOJ moves medical cannabis to Schedule III; biotech firms eye funding and IPOs amid banking and tax uncertainty.

The federal government’s reclassification of medical marijuana products as Schedule III drugs doesn’t federally legalize marijuana, but it might extend tax breaks to some cannabis businesses. ...

How big is the Black-owned cannabis market? The legal cannabis industry generates billions of dollars annually—reaching an ...

Researchers at Johns Hopkins and the UC San Diego used artificial intelligence to analyze comments in the public record ...

Trump administration to reclassify marijuana as Schedule III, easing research barriers but not legalizing the drug or ...

The iconic High Times Cannabis Cup competition heads to Atlantic City as New Jersey’s legal cannabis market gains momentum ...

The U.S. Department of Justice has rescheduled certain cannabis-based medicines, easing banking and tax barriers, while the ...

Mike Braun on Tuesday signaled a willingness to consider legalizing marijuana and cannabis products, which a new report says ...